The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
The new landscape of treatments for metastatic clear cell renal carcinoma (mRCC) is constantly expanding, but it is associated with the emergence of novel toxicities, adding to up to those observed in the tyrosine-kinase inhibitor (TKI) era. Indeed, the introduction of immune checkpoint inhibitors (...
Main Authors: | Michela Roberto, Martina Panebianco, Anna Maria Aschelter, Dorelsa Buccilli, Carmen Cantisani, Salvatore Caponnetto, Enrico Cortesi, Sara d’Amuri, Claudia Fofi, Debora Ierinò, Viviana Maestrini, Paolo Marchetti, Massimo Marignani, Antonio Stigliano, Luca Vivona, Daniele Santini, Silverio Tomao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1026978/full |
Similar Items
-
Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis
by: Ryota Morinaga, et al.
Published: (2019-08-01) -
An overview on occurrence of polycyclic aromatic hydrocarbons in food chain with special emphasis on human health ailments
by: Sombiri Sombiri, et al.
Published: (2024-07-01) -
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
by: Agnese Paderi, et al.
Published: (2021-08-01) -
Mapping the UK renal psychosocial workforce: the first comprehensive workforce survey
by: Maaike L. Seekles, et al.
Published: (2019-03-01) -
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
by: Yongchang Lai, et al.
Published: (2018-03-01)